We plan to study this candidate first as a monotherapy. po = per os (oral administration) and qd = daily. In (upper right) each animal is represented as a separate bar. Numerous unmet needs in RAS-addicted cancers may be served by a RASMULTI inhibitor. RMC-6236 caused regressions in preclinical xenograft model of tumors harboring KRASG12V . Each animal is represented as a separate bar. Demographic and baseline characteristics information is shown in Table 1. Abbreviations: SMQ, Standardized MedDRA Query; CMQ, Customized MedDRA Query. * Includes hemoglobin count decrease. ** A second patient had pneumonia which is not an expected event for RMC-4630. For all patients with KRASMUTANT NSCLC, DCR was 17/29 (59%) (Figure 12). Best change in tumor burden from baseline in KRASMUTANT non-small cell lung cancer. We plan to provide RMC-4630 to support this investigator-sponsored study. Orphan drug designation must be requested before submitting an NDA. These developments may delay our clinical trial timelines. Since inception, we have incurred significant net losses. There is a high failure rate for drugs proceeding through clinical trials. In many countries, the pricing review period begins after marketing approval is granted. The applicable period is seven years in the United States and ten years in Europe. Penalties for violations of these laws vary and may be significant. In addition, quality issues may arise during scale-up activities and at any other time. Moreover, the length of the extension could be less than we request. We may not be able to protect our intellectual property rights throughout the world. This could limit our potential revenue opportunities. In certain circumstances, we rely on our licensors and collaborators to pay these fees. We are highly dependent on members of our executive team. We currently do not have a marketing or sales organization. An active and liquid market for our common stock may not be sustained. We currently intend to invest our future earnings, if any, to fund our growth.